Business Wire

Parisian Concept Stores in the Spotlight for the Paris Retail Tour by Paris Retail Week

20.8.2015 09:11 | Business Wire

Del

Alongside the Paris Retail Week event that will be held this September 21-23, and echoing the E-Commerce Paris and Digital(in)Store by Equipmag tradeshows, Comexposium launches Paris Retail Tour for a total immersion in today’s innovative and connected store.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150820005395/en/

The first Paris Retail Tour, organized by Paris Retail Week, will be held on Tuesday, Sept. 22, 2015 from 9 am to 3 pm. The tour will showcase new trends and retail services present in modern Parisian stores.

During this inspirational day, stores and brands’ top managers, French and international, will visit a selection of 8 stores located in the heart of Paris. The tour provides an opportunity to see best-practices in motion and meet store representatives to get their feedback.

These shops were chosen for their innovative concepts, the new technologies implemented, a differentiating design or by their unique services.

These digital, consumer-centric innovations offer:

• For their customers, new experiences to be shared with friends on social media

• The ability to consume anytime, anywhere, and on any device with new apps for use in mobile payment, stock monitoring, click-and-collect and more

• For retailers, ways to make their customers more loyal right up to the point of sales, and to maintain contact across multiple channels thanks to new digital tools

• The latest technologies for retailers, such as RFID, 3D and IBeacon

These new devices are designed to attract visitors and escort them through their purchase, making the in store experience unique, global and seamless.

PARIS RETAIL TOUR - SUMMARY

September 22nd, 2015 – from 9 am to 3 pm

The Paris Retail Tour by Paris Retail Week will gather 30 French and international brands and participating stores’ top managers.

Coaching will be conducted by Cécile Delettré, international marketing and retail expert.

The visited concept stores, connected stores and brands names will be revealed to attendees the week before the Store Tour.

Fees: €300 incl. VAT before August 28th / €360 incl. VAT after August 28th. Lunch included.

Sign up here

About COMEXPOSIUM :

COMEXPOSIUM, one of the leading European event organizers, is involved in the organization of 114 mainstream and B2B events, covering 17 business industries. Every year, the Comexposium Group welcomes 38,000 exhibitors (40% of them international) and 3.5 million attendees (350,000 from abroad).

Comexposium organizes 5 of the 10 largest French events: SIAL, Intermat, Salon International de l'Agriculture, SIMA, Foire de Paris.
http://en.comexposium.com/

Contact information

Media contacts
USA
OXYGEN
Chris Orris / Maiwenn Regnault, +1 (630) 294-6645
chris@oxygen-pr.com / maiwenn@oxygen-pr.com
or
UK
PROMOSALONS UK
Elise EECKEMAN, +44 020 8216 3108
Elise@promosalons.co.uk

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 07:08Pressemelding

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom